$29.96
4.71%
Nasdaq, Nov 20, 04:00 pm EST. Closed.
ISIN
US92790C1045
Symbol
VRDN

Viridian Therapeutics Inc Stock price

$29.96
+7.53 33.57% 1M
+12.33 69.94% 6M
-1.16 3.73% YTD
+0.49 1.66% 1Y
+13.77 85.05% 3Y
+10.34 52.70% 5Y
-110.74 78.71% 10Y
-2,015.29 98.54% 20Y
Nasdaq, Closing price Fri, Nov 20 2026
-1.48 4.71%
ISIN
US92790C1045
Symbol
VRDN
Industry

Is Viridian Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,086 stocks worldwide.

Key metrics

Basic
Market capitalization
$3.2b
Enterprise Value
$2.6b
Net debt
positive
Cash
$981.5m
Shares outstanding
113.2m
Valuation
P/E
negative
P/S | estimate
45.5 | 43.5
EV/Sales | estimate
36.7 | 35.1
EV/FCF | ex SBC
negative | negative
P/B
4.9
Financial Health
Equity Ratio
80.3%
Return on Equity
-47.4%
ROCE
-39.2%
ROIC
-
Debt/Equity
0.5
Share-Based Compensation & Dilution
SBC | % of Revenue
$53.6m | 75.4%
SBC as % of FCF
-
SBC Growth 1Y
38.3%
Share Count Growth 1Y
38.7%
Shareholder Yield
-38.7%
Financials
Revenue | estimate
$71.1m | $74.4m
EBITDA
$-404.7m
EBIT
$-405.2m
Net Income
$-387.0m
Free Cash Flow | ex SBC
$-335.0m | $-388.7m
Growth
Revenue | estimate
22,845.2% | 5.0%
EBITDA
-9.1%
EBIT
-9.0%
Net Income
-12.5%
Free Cash Flow
-8.2%
Margin
Gross
-
EBITDA
-569.0%
EBIT
-569.7%
Net
-544.1%
Free Cash Flow | ex SBC
-471.0% | -546.4%
More
EPS
$-3.6
FCF per Share
$-3.0
Short interest
15.6%
Employees
252
Rev per Employee
$280.0k

Viridian Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Viridian Therapeutics Inc forecast:

22x Buy
96%
1x Hold
4%

Analyst Opinions

23 Analysts have issued a Viridian Therapeutics Inc forecast:

Buy
96%
Hold
4%

Viridian Therapeutics Inc Events

Past Events
NOV
9
Special Call - Viridian Therapeutics, Inc.
13 days ago
NOV
4
Q3 2026 Earnings Call
18 days ago
JUN
29
Special Call - Viridian Therapeutics, Inc.
5 months ago
JUN
9
Goldman Sachs 47th Annual Global Healthcare Conference 2026
6 months ago
MAY
5
Special Call - Viridian Therapeutics, Inc.
7 months ago
MAR
30
Special Call - Viridian Therapeutics, Inc.
8 months ago

Financial data from Viridian Therapeutics Inc

Jun '26
+/-
%
71 71
22,845% 22,845%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 152 152
125% 125%
213%
- Research and Development Expense 325 325
7% 7%
456%
-405 -405
9% 9%
-569%
- Depreciation and Amortization 0.47 0.47
2% 2%
1%
EBIT (Operating Income) EBIT -405 -405
9% 9%
-570%
Net Profit -387 -387
12% 12%
-544%

In millions USD.

Don't miss a Thing! We will send you all news about Viridian Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viridian Therapeutics Inc Stock News

Positive
Proactive Investors
●
2 days ago
Bank of America (BofA) has initiated coverage of Viridian Therapeutics (Nasdaq: VRDN) with a 'buy' rating and a $47 price objective, citing the potential of its thyroid eye disease treatments to capture market share and expand an undertreated market. The brokerage sees strong commercial prospects for Lumvoa, which is emerging as a challenger to Amgen's Tepezza, the current standard of care with...
Neutral
Business Wire
●
13 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced positive phase 1 results for VRDN-008. “Today's VRDN-008 data exceeded expectations and demonstrates a potentially transformative FcRn-inhibitor profile. Ba...
More Viridian Therapeutics Inc News

Company Profile

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma; and remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.

Head office United States
CEO Mr. Mahoney
Employees 252
Founded 2006
Website www.viridiantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today